PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF HEPTCELL (ADJUVANTED FP-02.2) AS AN IMMUNOTHERAPEUTIC VACCINE IN TREATMENT NAÏVE PATIENTS WITH INACTIVE CHRONIC HEPATITIS B (CHB)

Registry ID

ALT-301-202

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

ALTIMMUNE, INC.

Start date

2021-09-16

Last update

2020-10-02

Conditions

• CHRONIC HEPATITIS B

Related clinical trials

• PHASE II INVESTIGATOR-INITIATED STUDY TO UNDERSTAND THE VACCINAL EFFECT OF HBSAG MONOCLONAL AB VIR-3434 IN CHRONIC HEPATITIS B INFECTION

View on source registry